News

Excluding interest, depreciation and stock-based compensation on a non-GAAP basis, the Company had net income of $203,698 for the first quarter of 2009 compared to $338,310 for the

Sales in emerging markets represented 26 % of the total of sales recorded in this quarter. Operating charges break down into sales and marketing expenses (EUR1.83 million), general

Investigators for the upcoming Clarification of Optimal Anticoagulation through Genetics Trial (COAG Trial) have selected Osmetech’s Warfarin Sensitivity Tests and eSensor XT-8 molecular diagnostics instrument platform for ten

Swiss biopharmaceutical company Actelion has reported that the Independent Data and Safety Monitoring Board or DSMB has recommended continuation of the pivotal Phase III study BUILD-3, evaluating the

Entellus Medical, a medical technology company, has started enrollment in the FinESS Registry, a prospective, post-approval registry study designed to assess subject rhinosinusitis symptomatic status of up to

US-based Sadra Medical, a developer of new therapies for the treatment of aortic valve disease, has raised $30m in new investment capital. The round was led by Accuitive

In his position at SRI, he also developed technologies for vibration and acoustic control of large-scale systems. “We are pleased to add Gary Guthart to the company’s board,”

Amsterdam Molecular Therapeutics or AMT, a Netherlands-based company engaged in the development of human gene therapy, has initiated treatment of the first patient in a preregistration clinical trial

Canadian biopharmaceutical company Tekmira Pharmaceuticals has reported that its investigational new drug or IND application for ApoB SNALP has received clearance from the FDA allowing it to begin